(Q53588275)

15 May 2018

title

Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. (English)

1 reference

15 May 2018

2

John Fantasia

1 reference

15 May 2018

author name string

Salvatore L Ruggiero

series ordinal

1

1 reference

15 May 2018

Eric Carlson

series ordinal

3

1 reference

15 May 2018

publication date

31 July 2006

1 reference

15 May 2018

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

published in

1 reference

15 May 2018

volume

102

1 reference

15 May 2018

issue

4

1 reference

15 May 2018

page(s)

433-441

1 reference

15 May 2018

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Osteonecrosis and bisphosphonates: correlation versus causation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Intravenous bisphosphonates and osteonecrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphonate-associated oral osteonecrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Osteonecrosis of the jaw and bisphosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Avascular necrosis of the jaws: risk factors in metastatic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphonates: mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Ten years' experience with alendronate for osteoporosis in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Treatment of Paget's disease--taming the wild osteoclast.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2006.06.004

10.1016/J.TRIPLEO.2006.06.004

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018